Alprazolam 0.25mg tablets recalled for potential cross contamination
Preferred Pharmaceuticals is recalling Alprazolam 0.25mg tablets (Lot G1822K, expiration 5/31/2023) nationwide due to potential cross contamination from manufacturing deviations. No illnesses have been reported.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with manufacturing deviations creating potential cross-contamination risk, classified as a risk-of-harm product where injury has not yet been reported. No illnesses or injuries have been reported.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Alprazolam tablets, USP 0.25mg in 30-count bottles (NDC 68788-7594-3, Lot G1822K, expiration date 5/31/2023). The product is a prescription benzodiazepine medication.
The recall is a downstream action resulting from manufacturing deviations at Breckenridge Pharmaceuticals, Inc., which manufactures the product. These deviations created a potential risk of cross contamination during production.
The affected product was distributed nationwide in the United States. No illnesses or injuries have been reported to date. Consumers who have this medication should consult their healthcare provider about whether to continue use and proper disposal options. Healthcare providers should inform patients who may have received this lot.
The recalled product
- Product
- Alprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. Ins:NDC 68788-7594-3
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Benzodiazepine
- Affected units
- 30
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: G1822K
- Exp. Date:5/31/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Preferred Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
Same hazard · cross contamination
See all →- HighFDA Recalls Performance Pro Nitrile Gloves Due to Defects
FDA (Devices) · 2026-10-07
- HighFDA Recalls Opportunity Pro Nitrile Gloves Due to Manufacturing Defects
FDA (Devices) · 2026-10-07
- HighFDA Recalls Defective Blue Nitrile Patient Examination Gloves
FDA (Devices) · 2026-10-07
- ModerateSage Products Recalls Chlorhexidine Gluconate Cloth Due to Cross Contamination
FDA (Drugs) · 2026-09-09
- CriticalCetirizine Hydrochloride Tablets Recalled Due to Cross Contamination with Ranitidine
FDA (Drugs) · 2026-07-29
Similar recalls
- HighAlprazolam Tablets Recalled for Potential Cross-Contamination Risk
FDA (Drugs) · 2023-03-22
- HighAlprazolam Tablets Recalled Due to Potential Cross-Contamination Risk
FDA (Drugs) · 2023-03-22
- HighAlprazolam Tablets Recalled for Potential Cross-Contamination from Manufacturing Deviations
FDA (Drugs) · 2023-03-22
- HighAlprazolam 0.5 mg tablets recalled due to manufacturing contamination
FDA (Drugs) · 2023-04-12
- ModerateAlprazolam 2 mg tablets recalled due to potential cross-contamination
FDA (Drugs) · 2022-03-16
- ModerateAlprazolam Tablets Recalled Due to Potential Cross-Contamination
FDA (Drugs) · 2022-03-23